Bruce Booth is one of the best connected people to the business of biotech – great new write up on the coming tidal wave of immune-oncology new therapies (many about to be published), from a VC business perspective (The story is from Forbes)http://www.forbes.com/sites/brucebooth/ ... e-surface/
It is my personal believe that the oncology field 10 years from now will look completely different than it does now – using chemotherapy as the backbone of cancer treatment will look like the dark ages, similar to looking like the ancient medical history of iron lungs etc.
Just about every major company & research institute is spending vast amounts of money and strongly focusing their oncology scientists & scientific/financial resources on this research.
People ask me where my optimism comes from. In addition to Faith, this is where my optimism comes from. CRC is one of the tougher cases to crack with immune-oncology but with that amount of financial & scientific power thrown at the (large patient population in high need) problem, I can’t help but feel optimistic.
6/4/2012 Dx Stage 3C CRC @ 40 yo. MSS, KRAS-WT, BRAF-WT, p53-mut
8/13 Enlarged lymphs - Stable
10/14 Stage IV. Lung & Lymph mets. 5-FU+bev
11/15 FOLFIRI + bev
11/16 Signs of FOLFIRI resistance (Lymph mets)
1/17 Palliative radiation for resistant mets
2/17 FOLFIRI + bev + Maraviroc (off-label)
3/17 FOLFIRI + Erbitux + Maraviroc (off-label)MSS-CRC Clinical Trial Finder: http://trialfinder.fightcrc.org/2016 Colondar 2.0 ModelDK37 Science Posts List